Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib, Lenalidomide, and Dexamethasone in Multiple Myeloma (US MM-6)
NCT03173092Phase 4Terminated
- Sponsor
- Takeda
- Start
- Nov 2017
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixazomib in multiple myeloma (MM), sponsored by Takeda. Primary endpoint: Progression Free Survival up to 2 years. Started Nov 2017; status: terminated.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03173092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173092.